AI answer that might help explain the context and benefits of switching from anti inflammatory M2 macrophages to inflammatory M1 macrophages:

"Yes, in cancer, M2 macrophages are indeed recruited to the tumor microenvironment through the CCR5 receptor, which is activated by the chemokine CCL5 secreted by cancer cells, essentially protecting the cancer cells from inflammation by promoting an anti-inflammatory environment and supporting tumor growth; this mechanism is a key aspect of how tumors manipulate the immune system to facilitate their progression."

It is one of Leronlimab's mechanisms of action against cancer. By blocking the CCR5 receptors, the anti-inflammatory M2 macrophages are re-polarized to inflammatory macrophages (regulated). These inflammatory macrophages will attack, and kill, the cancer cells.